Chronic Pain Market

DelveInsight’s ‘Chronic Pain Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of chronic pain, historical and forecasted epidemiology, as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

 

The chronic pain market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted chronic pain symptoms market size from 2019 to 2032, segmented by seven major markets. The report also covers current chronic pain symptoms treatment practice/algorithms, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered

  • The United States
  • The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Chronic Pain Disease Understanding and Treatment Algorithm

Chronic Pain Overview

The International Association for the Study of Pain (IASP) defines pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. It may be due to an injury or the brain’s inability to process pain signals properly. Chronic pain can range from mild to severe and is present for long periods (>3 months) and is often the result of a disease that may require ongoing treatment. The most common sources of chronic pain include low back pain, musculoskeletal pain, migraines, fibromyalgia, neuralgia, cancer pain, visceral, and postoperative pain. With many chronic conditions, the cause of the pain is unknown.

 

Chronic Pain Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the chronic pain market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

 

DelveInsight’s chronic pain market report thoroughly understands chronic pain symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides chronic pain treatment algorithms and treatment guidelines for chronic pain symptoms in the US, Europe, and Japan.

 

There are several categories of medications that are used for the treatment of chronic pain. Oral medications include those that can be taken by mouth, such as nonsteroidal anti-inflammatory drugs, acetaminophen, opioids, opioid-like agents, or combinations of opioids and non-narcotic analgesics, corticosteroids, antirheumatics/immunological agents, and anticonvulsants. Opioids are most useful and usually reserved for chronic pain cases when other pain relievers are ineffective and when the negative side effects are manageable. Many chronic pain patients may benefit from taking antidepressant drugs. Types of antidepressants prescribed include tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), and others.

 

A few major unmet needs in the market include maintaining a balance between pain relief and side effects, lack of standardized tools to assess functional impairment, gaps in proper diagnosis and understanding, challenging diagnosis, absence of pain biomarkers, misperception and limited knowledge and lack of individualized treatment

Chronic Pain Epidemiology

The chronic pain symptoms epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and its trends and assumptions.

 

Key Findings

The total prevalent cases of chronic pain patients in the 7MM will increase during the study period, i.e., 2019–2032.

 

The disease epidemiology covered in the report provides historical as well as forecasted chronic pain symptoms epidemiology segmented as the total prevalent cases of chronic pain, severity-specific cases of chronic pain, age-specific cases of chronic pain, and cause-specific cases of chronic pain. The report includes the prevalent cases scenario of chronic pain in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Chronic Pain Epidemiology

Country-wise Chronic Pain Epidemiology

The epidemiology segment also provides the chronic pain epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The prevalent cases of chronic pain associated in 7MM countries were around 174 million in 2021.

Chronic Pain Drug Chapters

The chronic pain report’s drug chapter segment encloses the detailed analysis of chronic pain early-stage (Phase II and III) pipeline drugs. It also helps understand the chronic pain clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Chronic Pain Emerging Drugs

 

Atogepant: Allergan/AbbVie

Atogepant is an orally administered, small-molecule Calcitonin Gene-related Peptide (CGRP) receptor antagonist (Gepant) developed explicitly for the preventive treatment of migraine. CGRP and its receptors are expressed in regions of the nervous system associated with migraine pathophysiology.

 

A Pivotal Phase III study evaluating atogepant in adult patients with chronic migraine was completed and met its primary endpoint. In June 2022, AbbVie submitted a supplemental New Drug Application (sNDA) for atogepant (QULIPTA) to FDA to support the preventive treatment of chronic migraine in adults.

 

ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals Ltd.

Pentosan polysulfate sodium (PPS) is a semi-synthetic drug manufactured from the wood chips of European beech trees. Key features of PPS activity are its anti-inflammatory and tissue regenerative properties and its mild anti-thrombotic activity.

 

In May 2022, Paradigm reported that the first subjects have been randomized and dosed in the US in the PARA_OA_002 pivotal Phase III clinical trial, evaluating injectable PPS/ZILOSUL for the treatment of pain associated with knee osteoarthritis (kOA).

 

In April 2022, Paradigm Biopharmaceuticals Ltd. announced that the FDA had granted Fast Track Designation for the company's Phase III program investigating PPS for the treatment of osteoarthritis.

Other Products detailed in the report…

Chronic Pain Market Share

Chronic Pain Market Outlook

The report’s chronic pain market outlook helps understand the historic, current, and forecasted chronic pain market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

 

This segment gives a thorough detail of the chronic pain market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

 

According to DelveInsight, the chronic pain market in the 7MM is expected to grow steadily during the study period 2019–2032.

 

There are multiple pharmacological, adjunct, non-pharmacological, and interventional treatments for chronic, severe, and persistent pain. The list of pharmacological options for chronic pain is extensive, and this list includes non-opioid analgesics such as nonsteroidal anti-inflammatories (NSAIDs), acetaminophen, and aspirin. Medications such as tramadol, opioids, and antiepileptic drugs (gabapentin or pregabalin) can be useful. Furthermore, antidepressants such as tricyclic antidepressants and SNRIs, topical analgesics, muscle relaxers, N-methyl-d-aspartate (NMDA) receptor antagonists, and alpha 2 adrenergic agonists are also possible pharmacological therapies.

 

Drugs recently approved for the treatment of chronic pain due to different indications include Emgality (galcanezumab-gnlm), Aimovig (Eptinezumab), Tarlige (Mirogabalin besylate), Aimovig (Erenumab-aooe), and Ajovy (Fremanezumab), Vyepti (Eptinezumab), and Pennsaid gel.

 

Key Findings

This section includes a glimpse of the chronic pain market in the 7MM.

 

The chronic pain market size in the seven major markets was over USD 20 billion in 2021.

 

The United States Market Outlook

This section provides the total chronic pain market size and market size by therapies in the United States.

 

The United States accounts for the largest market size of chronic pain compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

The EU5 Countries: Market Outlook

The total chronic pain market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total chronic pain market size and market size by therapies in Japan are also mentioned.

Chronic Pain Market

Chronic Pain Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to be launched in the market during 2019–2032. The analysis covers the chronic pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

 

This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Pain Pipeline Development Activities

The chronic pain pipeline insight provides details into the therapeutic candidate in Phase I, II, and III stages. It also analyses chronic pain key players involved in developing targeted therapeutics.

 

Major market players include AbbVie, Paradigm Biopharmaceuticals Ltd, Noven Pharmaceuticals, Inc., among others.

 

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for chronic pain emerging therapies.

 

In March 2021, Paradigm Biopharmaceuticals Ltd. executed a new collaboration agreement with bene pharmaChem, which allows for the further development of injectable pentosan polysulfate sodium (iPPS) and other formulations containing PPS to address unmet needs in new clinical indications.

 

Under the new agreement, both parties have agreed to jointly fund the R&D and work collaboratively on new intellectual property creation, which Paradigm will commercialize

Reimbursement Scenario in Chronic Pain

Proactively approaching reimbursement can positively impact both during the early stages of product development and after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select markets with better market access can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the chronic pain domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or chronic pain market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the chronic pain Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

Market Size

USD xxxx Million in 2021.

Key Companies

AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Inc., Pfizer, Anika Therapeutics, Inc., Biogen, Tonix Pharmaceuticals, Inc., Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others.

Scope of the Report

  • The report covers a descriptive overview of chronic pain, explaining its causes, signs and symptoms, physiology, and currently available therapies.
  • Comprehensive insight into the chronic pain epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of the current and emerging therapies for chronic pain is provided, along with the assessment of new therapies that will impact the current treatment landscape.
  • A detailed review of the chronic pain market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global chronic pain market.

Report Highlights

  • In the coming years, the chronic pain market is set to change due to the rising awareness of the disease, the development of diagnostic techniques, and the favorable environment from regulators for innovative first-in-class curative drugs, and are likely to expand the market’s size and enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence chronic pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for chronic pain. The launch of emerging therapies will significantly impact the chronic pain market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Chronic Pain Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Chronic Pain Pipeline Analysis
  • Chronic Pain Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic Pain Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Chronic Pain Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Chronic Pain Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness

Key Questions

Market Insights:

  • What was the chronic pain Market share (%) distribution in 2019, and how would it look in 2032?
  • What would be the chronic pain total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
  • What are the key findings of the market across the 7MM, and which country will have the largest chronic pain market size during the forecast period (2019–2032)?
  • At what CAGR the chronic pain market is expected to grow in the 7MM during the forecast period (2019–2032)?
  • What would be the chronic pain market outlook across the 7MM during the forecast period (2019–2032)?
  • What would be the chronic pain market growth till 2032, and what will be the resultant market size in 2032?

 

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of chronic pain?
  • What is the historical chronic pain patient pool in seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, the UK), and Japan?
  • What would be the forecasted patient pool of chronic pain in seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, the UK), and Japan?
  • Out of all 7MM countries, which country would have the largest prevalent population of chronic pain during the forecast period (2019–2032)?
  • At what CAGR is the population expected to grow in the 7MM during the forecast period (2019–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of chronic pain along with the approved therapy?
  • What are the current treatment guidelines for treating chronic pain in the US, Europe, and Japan?
  • What are chronic pain marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of chronic pain?
  • How many therapies are developed by each company for the treatment of chronic pain?
  • How many emerging therapies are in the mid-stage and late stages of development to treat chronic pain?
  • What are the key collaborations (Industry–Industry, Industry–Academia), mergers and acquisitions, and licensing activities related to chronic pain therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for chronic pain and their status?
  • What key designations have been granted for emerging therapies for chronic pain?
  • What are the global historical and forecasted markets for chronic pain?

Reasons to buy

  • The report will help develop business strategies by understanding trends shaping and driving the chronic pain market.
  • To understand the future market competition in the chronic pain market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for chronic pain in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the chronic pain market.
  • To understand the future market competition in the chronic pain market.

1. Key Insights

2. Report Introduction

3. Chronic Pain Market Overview at a Glance

3.1. Market Share (%) Distribution of Chronic Pain in 2019

3.2. Market Share (%) Distribution of Chronic Pain in 2032

4. Executive Summary of Chronic Pain

5. Disease Background and Overview

5.1. Introduction

5.2. Classification of Chronic Pain

5.3. Characteristic Signs and Symptoms of Chronic Pain

5.3.1. Cancer Pain

5.3.2. Post-operative pain

5.3.3. Neuropathic pain

5.3.4. Chronic headache

5.3.5. Chronic visceral pain

5.3.6. Musculoskeletal (MSK) pain

5.3.7. Fibromyalgia

5.3.8. Osteoarthritis (OA)

5.3.9. Rheumatoid arthritis (RA)

5.3.10. Chronic low back pain

5.4. Risk Factors and Causes of Chronic Pain

5.5. Pathogenesis

5.6. Diagnosis of Chronic Pain

5.6.1. Physical, neurological, and mental health exams

5.6.2. Blood tests and urine analysis

5.6.3. Imaging tests

5.6.4. Nerve tests

5.7. Differential Diagnosis

5.8. Management

5.9. Clinical Practice Guidelines

5.9.1. Diagnostic guidelines

5.9.2. Management Guidelines

6. Epidemiology and Patient Population

6.1. The 7MM Total Prevalent Population of Chronic Pain

6.2. Key Findings

6.3. Assumptions and Rationale

6.4. The United States

6.4.1. Total Prevalent Cases of Chronic Pain in the United States

6.4.2. Severity-specific Cases of Chronic Pain in the United States

6.4.3. Age-specific Cases of Chronic Pain in the United States

6.4.4. Cause-specific Cases of Chronic Pain in the United States

6.5. The EU5

6.5.1. Total Prevalent Cases of Chronic Pain in the EU5

6.5.2. Severity-specific Cases of Chronic Pain in the EU5

6.5.3. Age-specific Cases of Chronic Pain in the EU5

6.5.4. Cause-specific Cases of Chronic Pain in the EU5

6.6. Japan

6.6.1. Total Prevalent Cases of Chronic Pain in Japan

6.6.2. Severity-specific Cases of Chronic Pain in Japan

6.6.3. Age-specific Cases of Chronic Pain in Japan

6.6.4. Cause-specific Cases of Chronic Pain in Japan

7. Patient Journey

8. Marketed Products

8.1. JOYCLU (diclofenac etalhyaluronate sodium): Seikagaku Corporation/Chiltern International Inc.

8.1.1. Product description

8.1.2. Regulatory milestones

8.1.3. Other development activities

8.1.4. Clinical development

8.1.5. Safety and efficacy

8.1.6. Adverse events

8.1.7. Product profile

8.2. ZILRETTA (triamcinolone acetonide extended-release injectable suspension): Flexion Therapeutics, Inc.

8.2.1. Product description

8.2.2. Regulatory milestones

8.2.3. Other development activities

8.2.4. Clinical development

8.2.5. Safety and efficacy

8.2.6. Adverse events

8.2.7. Product profile

8.3. LYRICA (pregabalin): Pfizer

8.3.1. Product description

8.3.2. Regulatory milestones

8.3.3. Other development activities

8.3.4. Safety and efficacy

8.3.5. AEs

8.3.6. Product profile

8.4. EMGALITY (galcanezumab): Elli Lilly and Company

8.4.1. Product description

8.4.2. Regulatory milestones

8.4.3. Other development activities

8.4.4. Safety and efficacy

8.4.5. AEs

8.4.6. Ongoing current pipeline activity

8.4.7. Product profile

8.5. VYEPTI (eptinezumab): Lundbeck Seattle BioPharmaceutical

8.5.1. Drug description

8.5.2. Regulatory milestones

8.5.3. Safety and efficacy

8.5.4. AEs

8.5.5. Product profile

8.6. AIMOVIG (erenumab): Amgen/Novartis

8.6.1. Product profile

8.6.2. Regulatory milestones

8.6.3. Other developmental activities

8.6.4. Safety and efficacy

8.6.5. Ongoing current pipeline activity

8.6.6. AEs

8.6.7. Product profile

8.8. AJOVY (fremanezumab): Teva Pharmaceuticals

8.8.1. Product description

8.8.2. Regulatory milestones

8.8.3. Other developmental activities

8.8.4. Safety and efficacy

8.8.5. AEs

8.8.6. Product profile

8.9. PENNSAID Gel: Mallinckrodt

8.9.1. Product description

8.9.2. Regulatory milestone

8.9.3. Other developmental activities

8.9.4. Safety and efficacy

8.9.5. AE

8.9.6. Product profile

9. Emerging Therapies

9.1. Key Cross Competition

9.2. Atogepant: AbbVie

9.2.1. Drug description

9.2.2. Other development activities

9.2.3. Clinical development

9.2.4. Safety and efficacy

9.2.5. Product profile

9.3. ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals Ltd.

9.3.1. Drug description

9.3.2. Other development activities

9.3.3. Clinical development

9.3.4. Product profile

9.4. HP-5000 (Diclofenac sodium): Noven Pharmaceuticals, Inc.

9.4.1. Drug description

9.4.2. Other development activities

8.5.3. Safety and efficacy

8.5.4. AEs

8.5.5. Product profile

9.5. Reboxetine (AXS-14): Pfizer

9.5.1. Drug description

9.5.2. Other development activities

9.5.3. Clinical development

9.5.4. Safety and efficacy

9.5.5. Product profile

9.6. CINGAL: Anika Therapeutics, Inc.

9.6.1. Drug description

9.6.2. Other development activities

9.6.3. Clinical development

9.6.4. Safety and efficacy

9.6.5. Product profile

9.8. Vixotrigine (BIIB074): Biogen

9.8.1. Drug Description

9.8.2. Other Developmental Activities

9.8.3. Clinical Development

9.8.4. Safety and efficacy

9.8.5. Product profile

9.9. TNX-102 SL: Tonix Pharmaceuticals, Inc.

9.9.1. Drug description

9.9.2. Other development activities

9.9.3. Clinical development

9.9.4. Safety and efficacy

9.9.5. Product profile

9.10. TLC599: Taiwan Liposome Company

9.10.1. Drug description

9.10.2. Other development activities

9.10.3. Clinical development

9.10.4. Safety and efficacy

9.10.5. Product profile

9.11. CNTX-4975: Centrexion Therapeutics

9.11.1. Drug description

9.11.2. Other development activities

9.11.3. Clinical development

9.11.4. Clinical trial information

9.11.5. Safety and efficacy

9.11.6. Product profile

9.12. BRIXADI (Buprenorphine, CAM2038): Braeburn Pharmaceuticals

9.12.1. Drug description

9.12.2. Other development activities

9.12.3. Clinical development

9.12.4. Safety and efficacy

9.12.5. Product profile

9.13. Fasinumab: Regeneron, Teva Pharmaceuticals, and Mitsubishi Tanabe Pharma Corporation

9.13.1. Drug description

9.13.2. Other development activities

9.13.3. Clinical development

9.13.4. Safety and efficacy

9.13.5. Product profile

9.14. Dronabinol (VER-01): Vertanical GmbH

9.14.1. Drug description

9.14.2. Clinical development

9.14.3. Product profile

10. Other Promising Therapies

10.1. Other assets in development

10.2. CGS-200-5: Propella Therapeutics, Inc.

10.2.1. Drug description

10.2.2. Other development activities

10.2.3. Clinical development

10.2.4. Safety and efficacy

10.2.5. Product profile

10.4. AMZ001: Amzell

10.4.1. Drug description

10.4.2. Other development activities

10.4.3. Clinical development

10.4.4. Safety and efficacy

10.4.5. Product profile

10.5. Resiniferatoxin (RTX): Sorrento Therapeutics, Inc.

10.5.1. Drug description

10.5.2. Other development activities

10.5.3. Clinical development

10.5.4. Product profile

10.6. BAY2395840: Bayer

10.6.1. Drug description

10.6.2. Other development activities

10.6.3. Clinical development

10.6.4. Product profile

10.7. LX-9211: Lexicon Pharmaceuticals

10.7.1. Drug description

10.7.2. Other development activities

10.7.3. Clinical development

10.7.4. Safety and Efficacy

10.7.5. Product profile

10.8. QIXLEEF (PPP001): Tetra Bio-Pharma

10.8.1. Drug description

10.8.2. Other development activities

10.8.3. Clinical development

10.8.4. Product profile

10.9. CBD: Pure Green Pharmaceuticals, Inc.

10.9.1. Drug description

10.9.2. Clinical development

10.9.3. Safety and efficacy

10.9.4. Product profile

10.10. LY3556050 (CNTX-0290): Eli Lilly and Company

10.10.1. Drug description

10.10.2. Other development activities

10.10.3. Clinical development

10.10.4. Product profile

10.11. NFX88: Neurofix Pharma

10.11.1. Drug description

10.11.2. Other development activities

10.11.3. Clinical development

10.11.4. Product profile

10.12. STA363: Stayble Therapeutics

10.12.1. Drug description

10.12.2. Other development activities

10.12.3. Clinical development

10.12.4. Product profile

10.13. Lorecivivint (SM04690): Biosplice Therapeutics

10.13.1. Drug description

10.13.2. Other development activities

10.13.3. Clinical development

10.13.4. Safety and efficacy

10.13.5. Product profile

10.14. Halneuron: Wex Pharmaceuticals Inc.

10.14.1. Drug description

10.14.2. Clinical development

10.14.3. Safety and efficacy

10.14.4. Adverse events

10.14.5. Product profile

10.15. Sprifermin: EMD Serono Research & Development Institute, Inc./Nordic Bioscience A/S

10.15.1. Drug description

10.15.2. Other development activities

10.15.3. Clinical development

10.15.4. Safety and efficacy

10.15.5. Product profile

10.16. XT-150: Xalud Therapeutics, Inc.

10.16.1. Drug description

10.16.2. Other development activities

10.16.3. Clinical development

10.16.4. Product profile

10.17. Cebranopadol (PRK-101): Tris Pharma, Inc

10.17.1. Drug description

10.17.2. Other development activities

10.17.3. Clinical development

10.17.4. Safety and efficacy

10.17.5. Product profile

11. Chronic Pain: The Seven Major Market Analysis

11.1. Key Findings

11.2. Market Size of Chronic Pain in the 7MM

11.3. Market Outlook

11.4. The United States Market Size

11.4.1. Total Market Size of Chronic Pain in the United States

11.4.2. Market Size of Chronic Pain by Therapies in the United States

11.5. The EU5 Market

11.5.1. Total Market Size of Chronic Pain in the EU5

11.5.2. Market Size of Chronic Pain by Therapies in the EU5

11.6. Japan

11.6.1. Total Market Size of Chronic Pain in Japan

11.6.2. Market Size of Chronic Pain by Therapies in Japan

12. SWOT Analysis

13. Unmet Needs

14. KOL Views

15. Market Access and Reimbursement

15.1. Healthcare resource utilization

15.2. The United States

15.2.1. CMS pain management coverage

15.2.2. Manufacturer copay programs

15.2.3. Patient Access Programs

15.3. The EU5

15.3.1. The United Kingdom

15.4. Health Technology Assessment

15.4.1. National Institute for Health and Care Excellence (NICE)

15.4.2. Scottish Medicines Consortium (SMC)

15.4.3. ICER

16. Acronyms and Abbreviations

17. Appendix

17.1. Bibliography

17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Table

Table 1: Summary of Chronic Pain, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Classification of Chronic Pain

Table 3: Summary of Recommendations

Table 4: Recommendations

Table 5: Total Prevalent Population of Chronic Pain in the 7MM (2019–2032)

Table 6: Total Prevalent Cases of Chronic Pain in the United States (2019–2032)

Table 7: Severity-specific Cases of Chronic Pain in the United States (2019–2032)

Table 8: Age-specific Cases of Chronic Pain in the United States (2019–2032)

Table 9: Cause-specific Cases of Chronic Pain in the United States (2019–2032)

Table 10: Total Prevalent Cases of Chronic Pain in the EU5 (2019–2032)

Table 11: Severity-specific Cases of Chronic Pain in the EU5 (2019–2032)

Table 12: Age-specific Cases of Chronic Pain in the EU5 (2019–2032)

Table 13: Cause-specific Cases of Chronic Pain in the EU5 (2019–2032)

Table 14: Total Prevalent Cases of Chronic Pain in Japan (2019–2032)

Table 15: Severity-specific Cases of Chronic Pain in Japan (2019–2032)

Table 16: Age-specific Cases of Chronic Pain in Japan (2019–2032)

Table 17: Cause-specific Cases of Chronic Pain in Japan (2019–2032)

Table 18: JOYCLU, Clinical Trial Description, 2021

Table 19: FX006, Clinical Trial Description, 2021

Table 20: Galcanezumab, Clinical Trial Description, 2022

Table 21: AIMVOIG, Clinical Trial Description, 2022

Table 22: Key cross of emerging drugs

Table 23: Key cross of emerging drugs

Table 24: Key cross of emerging drugs

Table 25: Key cross of emerging drugs

Table 26: Atogepant, Clinical Trial Description, 2022

Table 27: ZILOSUL, Clinical Trial Description, 2022

Table 28: HP-5000, Clinical Trial Description, 2022

Table 29: Reboxetine, Clinical Trial Description, 2022

Table 30: CINGAL, Clinical Trial Description, 2022

Table 31: RTX-GRT7039, Clinical Trial Description, 2022

Table 32: BIIB074, Clinical Trial Description, 2022

Table 33: TNX-102 SL, Clinical Trial Description, 2022

Table 34: TLC599, Clinical Trial Description, 2021

Table 35: CNTX-4975, Clinical Trial Description, 2022

Table 36: BRIXADI, Clinical Trial Description, 2022

Table 37: Fasinumab, Clinical Trial Description, 2022

Table 38: Dronabinol, Clinical Trial Description, 2022

Table 39: Key cross of other assets

Table 40: Key cross of other assets

Table 41: Key cross of other assets

Table 42: Key cross of other assets

Table 43: CGS-200-5, Clinical Trial Description, 2022

Table 44: MIV-711, Clinical Trial Description, 2022

Table 45: AMZ001, Clinical Trial Description, 2022

Table 46: Resiniferatoxin, Clinical Trial Description, 2022

Table 47: BAY2395840, Clinical Trial Description, 2022

Table 48: LX9211, Clinical Trial Description, 2022

Table 49: QIXLEEF, Clinical Trial Description, 2022

Table 50: CBD, Clinical Trial Description, 2022

Table 51: LY3556050, Clinical Trial Description, 2022

Table 52: STA363, Clinical Trial Description, 2022

Table 53: Lorecivivint, Clinical Trial Description, 2022

Table 54: Halneuron, Clinical Trial Description, 2022

Table 55: Sprifermin, Clinical Trial Description, 2022

Table 56: XT-150, Clinical Trial Description, 2022

Table 57: Cebranopadol, Clinical Trial Description, 2022

Table 58: Market Size of Chronic Pain in the 7MM in USD million (2019–2032)

Table 59: Total Market Size of Chronic Pain in the United States in USD million (2019–2032)

Table 60: Market Size of Chronic Pain in the United States by Therapies in USD million (2019–2032)

Table 61: Total Market Size of Chronic Pain in the EU5 in USD million (2019–2032)

Table 62: Market Size of Chronic Pain in the EU5 by Therapies in USD million (2019–2032)

Table 63: Total Market Size of Chronic Pain in Japan in USD million (2019–2032)

Table 64: Market Size of Chronic Pain in Japan by Therapies in USD million (2019–2032)

Table 65: Patient Access Programs of Chronic Pain Drugs

List of Figures

Figure 1: Chronic Pain in ICD-11

Figure 2: Non-pain Symptoms/Signs Exhibited by Chronic Pain Patients

Figure 3: General Characteristics of Pain due to Visceral Pathology

Figure 4: Risk Factors of Chronic Pain

Figure 5: Pain Circuits and Some Manifestations of Chronic Pain

Figure 6: Sensory Neuron Interactions with Central Glial Cells in Neuropathic Pain

Figure 7: Central Sensitization Mechanisms

Figure 8: Recommended Therapies for the Management of OA

Figure 9: Total Prevalent Population of Chronic Pain in the 7MM (2019–2032)

Figure 10: Total Prevalent Cases of Chronic Pain in the United States (2019–2032)

Figure 11: Severity-specific Cases of Chronic Pain in the United States (2019–2032)

Figure 12: Age-specific Cases of Chronic Pain in the United States (2019–2032)

Figure 13: Cause-specific Cases of Chronic Pain in the United States (2019–2032)

Figure 14: Total Prevalent Cases of Chronic Pain in the EU5 (2019–2032)

Figure 15: Severity-specific Cases of Chronic Pain in the EU5 (2019–2032)

Figure 16: Age-specific Cases of Chronic Pain in the EU5 (2019–2032)

Figure 17: Cause-specific Cases of Chronic Pain in the EU5 (2019–2032)

Figure 18: Total Prevalent Cases of Chronic Pain in Japan (2019–2032)

Figure 19: Severity-specific Cases of Chronic Pain in Japan (2019–2032)

Figure 20: Age-specific Cases of Chronic Pain in Japan (2019–2032)

Figure 21: Cause-specific Cases of Chronic Pain in Japan (2019–2032)

Figure 22: Mechanism of action of Fasinumab

Figure 23: Mechanism of action of Lorecivivint

Figure 24: Mechanism of action of Halneuron

Figure 25: Market Size of Chronic Pain in the 7MM in USD million (2019–2032)

Figure 26: Total Market Size of Chronic Pain in the United States in USD million (2019–2032)

Figure 27: Market Size of Chronic Pain in the United States by Therapies in USD million (2019–2032)

Figure 28: Total Market Size of Chronic Pain in the EU5 in USD million (2019–2032)

Figure 29: Market Size of Chronic Pain in the EU5 by Therapies in USD million (2019–2032)

Figure 30: Total Market Size of Chronic Pain in Japan in USD million (2019–2032)

Figure 31: Market Size of Chronic Pain in Japan by Therapies in USD million (2019–2032)

AbbVie
Paradigm Biopharmaceuticals Ltd.
Noven Pharmaceuticals, Inc.
Pfizer
Anika Therapeutics, Inc.
Biogen
Tonix Pharmaceuticals, Inc.
Taiwan Liposome Company
Centrexion Therapeutics
Braeburn Pharmaceuticals
Regeneron
Teva Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation
Vertanical GmbH

 

Forward to Friend

Need A Quote